Ring DB - Search Results

1

Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.

Amoroso AR, Clark JI, Litwin S, Hsieh-Ma S, Shi T, Alpaugh RK, Adams GP, Wolf EJ, Ring DB, Weiner LM. Amoroso AR, et al. Among authors: ring db. Cancer Res. 1996 Jan 1;56(1):113-20. Cancer Res. 1996. PMID: 8548750

2

In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.

Hsieh-Ma ST, Eaton AM, Shi T, Ring DB. Hsieh-Ma ST, et al. Among authors: ring db. Cancer Res. 1992 Dec 15;52(24):6832-9. Cancer Res. 1992. PMID: 1360872

3

Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Weiner LM, et al. Among authors: ring db. Cancer Res. 1995 Oct 15;55(20):4586-93. Cancer Res. 1995. PMID: 7553634 Clinical Trial.

4

Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.

Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK. Weiner LM, et al. Among authors: ring db. J Immunol. 1993 Sep 1;151(5):2877-86. J Immunol. 1993. PMID: 8103070

5

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Weiner LM, Clark JI, Ring DB, Alpaugh RK. Weiner LM, et al. Among authors: ring db. J Hematother. 1995 Oct;4(5):453-6. doi: 10.1089/scd.1.1995.4.453. J Hematother. 1995. PMID: 8581384 Clinical Trial.

6

Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.

Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB, Barth MW. Weiner LM, et al. Among authors: ring db. Cancer Immunol Immunother. 1996 Mar;42(3):141-50. doi: 10.1007/s002620050264. Cancer Immunol Immunother. 1996. PMID: 8640842 Free PMC article.

7

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.

Clark JI, Alpaugh RK, von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM. Clark JI, et al. Among authors: ring db. Cancer Immunol Immunother. 1997 Jul;44(5):265-72. doi: 10.1007/s002620050382. Cancer Immunol Immunother. 1997. PMID: 9247561 Free PMC article. Clinical Trial.

8

Effector characteristics of the IgG3 murine monoclonal antibody 113F1.

Weiner LM, Zarou CM, O'Brien J, Ring D. Weiner LM, et al. J Biol Response Mod. 1989 Jun;8(3):227-37. J Biol Response Mod. 1989. PMID: 2787391

9

Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens.

Ring DB, Hsieh-Ma ST, Shi T, Reeder J. Ring DB, et al. Cancer Immunol Immunother. 1994 Jul;39(1):41-8. doi: 10.1007/BF01517179. Cancer Immunol Immunother. 1994. PMID: 8044825 Free PMC article.

10

Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein.

Shi T, Hsieh-Ma ST, Reeder J, Ring DB. Shi T, et al. Among authors: ring db. Clin Immunol Immunopathol. 1996 Feb;78(2):188-95. doi: 10.1006/clin.1996.0028. Clin Immunol Immunopathol. 1996. PMID: 8625561

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters